SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
PORT WASHINGTON, N.Y., Feb. 02, 2017 -- ACETO Corporation (Nasdaq:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced that it has appointed Vimal Kavuru, 48 years old, to its Board of Directors, effective February 2, 2017.
Chairman of the Board, Albert Eilender, commented, “We are pleased to welcome Vimal Kavuru to the ACETO Board of Directors. His vast experience in pharmaceuticals will be a tremendous asset for the Board and Company.”
Since 2013, Mr. Kavuru has been the CEO and a founder of Citron Pharma LLC and Lucid Pharma LLC, from which Aceto subsidiary Rising Pharmaceuticals acquired certain generic products and related assets in December 2016. In 2008, Mr. Kavuru founded Gen-Source RX, a generic pharmaceutical distributor, and served as CEO until 2014 when that business was sold to Cardinal Health. Since 2007, Mr. Kavuru has served as a director of Celon Labs Ltd., an Indian specialty pharmaceutical company focused on the oncology and critical care segments in India that he co-founded in 2007. Additionally, he has served as a director of Cronus Pharma LLC, an animal health pharmaceutical company, since 2016, is the founder of Casper Pharma LLC, an emerging specialty brand and injectable pharmaceutical company, and is a co-founder of Grace Therapeutics, a pharmaceutical company focused on treating rare and orphan diseases.
About ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact: LHA Jody Burfening [email protected] (212) 838-3777
